Proteon developing rDNA elastase for vascular surgery
This article was originally published in Scrip
Executive Summary
The private US firm Proteon Therapeutics is developing human recombinant elastase, PRT-201, for facilitating arteriovenous fistula surgery, and expects to start clinical trials this year. PRT-201 has just received fast-track designation from the FDA.